Related Experiment Videos
ER-D5 antigen in breast cancer
M A Navarro1, M Guardia, B Arranz
1Hormone Unit (Biochemistry Service), Hospital de Bellvitge, Barcelona, Spain.
Journal of Cancer Research and Clinical Oncology
|January 1, 1989
Summary
A new protein, estrogen-receptor-associated protein (ER-D5), correlates with estrogen and progesterone receptors in breast cancer patients. This finding suggests ER-D5 may aid in managing breast cancer.
Area of Science:
- Oncology
- Endocrinology
- Biochemistry
Background:
- Estrogen receptors (ER) and progesterone receptors (PgR) are key biomarkers in breast cancer management.
- Accurate receptor status is crucial for guiding treatment decisions.
- Novel biomarkers that correlate with ER and PgR status could enhance patient stratification.
Purpose of the Study:
- To investigate the correlation between a novel estrogen-receptor-associated protein (ER-D5) and established ER and PgR levels in primary breast carcinoma.
- To determine if ER-D5 serves as a potential complementary biomarker in breast cancer management.
Main Methods:
- Samples from 28 female patients with primary breast carcinoma were analyzed.
- Levels of ER-D5, estrogen receptors (ER), and progesterone receptors (PgR) were measured.
- Statistical correlation analyses were performed for premenopausal and postmenopausal subgroups.
Main Results:
- A significant positive correlation (r = 0.79) was observed between ER-D5 and ER, and between ER-D5 and PgR in premenopausal women.
- In postmenopausal women, a significant positive correlation (r = 0.75) was found only between ER-D5 and ER, not ER-D5 and PgR.
- These correlations suggest a relationship between ER-D5 and hormone receptor status.
Conclusions:
- ER-D5 shows a strong correlation with ER and PgR in premenopausal breast cancer patients.
- ER-D5 correlates with ER in postmenopausal breast cancer patients.
- Measurement of ER-D5 may offer a complementary approach to current methods in breast cancer management.